Moderna’s consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from analysts.
The company reported a higher-than-expected revenue of $1 billion for the fourth quarter but faced a GAAP net loss of $1.1 billion.
Moderna is developing new products, including a next-generation COVID vaccine, with a revenue forecast between $1.5 billion and $2.5 billion for 2025.
Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. The company is navigating a challenging period as it transitions from its COVID-19 vaccine success to introducing new products. Competitors in the biotech sector include Amgen, CRISPR Therapeutics, Sarepta Therapeutics, and Vertex Pharmaceuticals.
Over the past year, Moderna’s consensus price target has seen a significant decline. A year ago, analysts set the average price target at $119.26, but it has since dropped to $47.5. This shift indicates a more cautious outlook from analysts, possibly due to market conditions and company performance.
Despite reporting higher-than-expected revenue of $1 billion for the fourth quarter, Moderna faced a GAAP net loss of $1.1 billion. This loss includes $200 million in non-cash charges related to manufacturing resizing. The decrease in demand for its COVID vaccine has impacted the company’s financial performance.
Looking forward, Moderna anticipates its 2025 revenue to range between $1.5 billion and $2.5 billion. The company is also working on new products, including a next-generation COVID vaccine, an RSV vaccine, and a flu/COVID combination vaccine. These developments could influence future analyst sentiment.
Deutsche Bank analyst Emmanuel Papadakis has set a price target of $155 for Moderna, reflecting optimism in the company’s potential. As Moderna prepares to announce its fourth-quarter earnings, investors are closely watching for updates on its pipeline and any impact on its stock price.
